Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | DPP4 | P27487 | 2/20 | 0.56 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7714323 | 1.00 | CYP2D6 (0.70) | CYP2D6DPP4SRCLMNAMAPK1 | |
| SCHEMBL13931648 | 1.00 | CYP2D6 (0.70) | CYP2D6DPP4SRCLMNAMAPK1 | |
| SCHEMBL7040718 | 0.84 | ACP3 (0.53) | CYP2D6KMT2A | |
| SCHEMBL7824857 | 0.83 | CYP2D6 (1.00) | CYP2D6SRCLMNAMAPK1KMT2A | |
| SCHEMBL7815004 | 0.83 | CYP2D6 (1.00) | CYP2D6SRCLMNAMAPK1KMT2A | |
| SCHEMBL659768 | 0.83 | CYP2D6 (1.00) | CYP2D6SRCLMNAMAPK1KMT2A | |
| SCHEMBL11315838 | 0.83 | CYP2D6 (1.00) | CYP2D6SRCLMNAMAPK1KMT2A | |
| SCHEMBL7519804 | 0.82 | CYP2D6 (0.70) | CYP2D6DPP4SRCLMNAMAPK1 | |
| SCHEMBL2308229 | 0.82 | CYP2D6 (0.70) | CYP2D6DPP4SRCLMNAMAPK1 | |
| SCHEMBL27818755 | 0.80 | CYP2D6 (0.94) | CYP2D6SRCLMNAMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6521654-B2 | For therapy and prophylaxis of rheumatoid arthritis, or of allergic disorders, asthma, inflammation; inhibitors of the adhesion and migration of leucocytes and/or antagonists of adhesion receptor VLA-4 belonging to the integrins group | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-02-18 | — | — | US | disclosed |
| US-20020143043-A1 | Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations including them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143043-A1 | Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations including them | VCAM1, ITGA1, ITGA4 | CYP2D6 1024/4885DPP4 2387/4885SRC 1109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.